Your session is about to expire
← Back to Search
Quality Improvement Program
Quality Improvement Program for COPD (PREVAIL Trial)
N/A
Recruiting
Research Sponsored by Observational and Pragmatic Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during implementation and outcome evaluation period, 2.5 years
Awards & highlights
PREVAIL Trial Summary
This trial will test whether a quality improvement and clinical decision support package can improve outcomes for patients with modifiable high-risk chronic obstructive pulmonary disease.
Who is the study for?
This trial is for Primary Care Teams (PCTs) managing patients with high-risk chronic obstructive pulmonary disease (COPD). PCTs must not be involved in other COPD studies, planning to change their electronic health records provider or ownership during the study, and should be willing to potentially use a new quality improvement program.Check my eligibility
What is being tested?
The trial is testing the CONQUEST Quality Improvement Program over three years. It compares how well this program works against usual care for patients with modifiable high-risk COPD. Teams are randomly chosen to either start with CONQUEST or continue regular care before getting the program later.See study design
What are the potential side effects?
Since this trial focuses on a quality improvement program rather than a medication, it does not have traditional side effects. However, there may be indirect impacts on patient care processes and outcomes which will be monitored throughout the study.
PREVAIL Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ during implementation and outcome evaluation period, 2.5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during implementation and outcome evaluation period, 2.5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
1a: COPD Exacerbations and 1b) major cardiac or respiratory events
Secondary outcome measures
Systemic corticosteroid use (SCS)
Other outcome measures
Exploratory Objective 1: The rate of explanatory diagnoses other than COPD
Exploratory Objective 2: Lung function
Exploratory Objective 3: Health status
PREVAIL Trial Design
2Treatment groups
Experimental Treatment
Group I: Delayed Intervention ArmExperimental Treatment1 Intervention
The CONQUEST quality improvement program will be rolled-out to the delayed intervention practices at the end of the outcome evaluation period.
Group II: CONQUEST Intervention ArmExperimental Treatment1 Intervention
Intervention arm clusters will receive the CONQUEST quality improvement program.
Find a Location
Who is running the clinical trial?
Observational and Pragmatic Research InstituteLead Sponsor
The DARTNet Institute (DI)UNKNOWN
AstraZenecaIndustry Sponsor
4,265 Previous Clinical Trials
288,605,156 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- People who are currently involved in research or programs that could affect their participation in the CONQUEST program.I am open to being randomly assigned to either start with the CONQUEST program or receive usual care first.My condition meets the high-risk criteria that can be treated.You are in the process of changing your electronic health record software or planning to change the ownership of your medical practice during the trial evaluation period.
Research Study Groups:
This trial has the following groups:- Group 1: CONQUEST Intervention Arm
- Group 2: Delayed Intervention Arm
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is enrollment ongoing for this experiment?
"The clinical trial is actively recruiting, as indicated on the data posted in clinicaltrials.gov. This medical study was initially published on September 23rd 2022 and its most recent iteration went live on the 26th of that same month."
Answered by AI
What is the current number of participants involved in this research endeavor?
"Affirmative. The data available on clinicaltrials.gov specifies that this trial, first posted September 23rd 2022, is actively recruiting patients. A total of 126 participants are needed from one medical facility."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger